Academia Just Quietly Renamed B2B Sales. Most of the Field Did Not Notice.

The slide had a logo on it. MEDDIC, maybe. Challenger, SPIN, or a homegrown stage gate with a clever internal name. Under the logo, a chart. Close rate, trailing twelve months, drifting down and to the right.

The VP of Sales stood next to it and walked the room through the plan. More enablement. Tighter qualification. A refresher certification for the reps who slipped last quarter. Everyone nodded, because everyone in that room had been trained to believe the chart goes down when reps stop running the play.

Nobody asked the other question.

Nobody asked what the play was built on, or whether the ground under it had shifted.

That question matters more than the certification schedule, because the academic field that gave B2B sales its foundations has already moved on. The researchers who study how buyers actually buy have a new name for what selling is. Most of the industry running the old playbooks has not noticed the rename. And the deals dying in your pipeline right now are the first place it shows up.

The rename almost nobody on the floor heard

In 2025, four researchers published a paper in the Journal of Marketing, the most prestigious outlet in the field. Tim Kalwey, Manfred Krafft, Yeji Lim, and Murali Mantrala gave the current era of B2B selling a name: Holistic Selling.

Here is the part that should stop you. In their words, "the key role of the salesperson evolves from order getting or long-term relationship building to orchestrating all buyer-seller touchpoints." The core purpose, they write, "shifts to fostering the buyer's decision-making competence rather than order getting, digital conversions, or long-term partnering."

Read what that actually says. The job of the seller is no longer to get the order. It is to make the buyer better at deciding.

That is not a tweak to the script. That is a different definition of the work. The frameworks most revenue teams run were built around a seller who drives the interaction toward a close. The field that studies this now says the seller does not drive the interaction at all. The buyer does. The seller's job is to make the buyer's own decision process work.

If your methodology still treats the rep as the engine of the deal, you are not running a slightly dated version of the right idea. You are running the model the researchers retired.

Every methodology has a foundation date

Methodologies feel permanent when you are inside them. They are not. Each one was authored in a specific decade, for a specific buyer, in a specific information environment. BANT came out of an era when the seller held the information and the buyer needed the meeting to learn anything. MEDDIC, SPIN, Challenger, all of them assume a version of the buyer who shows up uninformed and gets shaped by a skilled rep across a series of conversations.

That buyer is gone.

Two structural shifts did it, and both are documented. Research in the Journal of the Academy of Marketing Science found that information asymmetry between buyer and seller has collapsed, and face-to-face is no longer the dominant way the two sides interact (Ahearne et al., 2021). Those two changes, the authors write, have rewritten buyer attitudes, seller effectiveness, and the entire nature of the interaction.

Sit with what that means for the playbook. The pressure tactics that BANT and aggressive qualification cadences were built to apply assume a buyer who can be moved by the rep's urgency. When that buyer instead arrives having already done the research, the pressure does not move them. It repels them. The legacy frameworks were not wrong for their time. They were built for a room that no longer exists.

This is the gap a diagnostic layer fills and a methodology cannot. The methodology tells you how to run the conversation. It says nothing about whether the buyer was ever in a position to decide.

The receipt arrives as a stalled pipeline

Here is what the aging frame costs, and it does not show up as a competitor stealing your deal. It shows up as nothing happening at all.

Start with where the buyer is before your rep ever picks up the phone. By 2025, buyers were purchasing from one of the four vendors on their Day One shortlist 95 percent of the time, up from 85 percent the year before (6sense, 2025). The shortlist forms before the conversation. The conversation does not build it. And research in the Annals of Operations Research confirms buyers form their judgments pre-engagement, while most suppliers never monitor that phase at all (Kumar et al., 2022). The most decisive part of the buyer's decision is the part your methodology has no instrument for.

Then comes the loss. Not to a rival. To indecision. 56 percent of inaction losses come from buyer indecision, not from a preference for the status quo (Dixon and McKenna, Harvard Business Review, 2022). Other industry data puts the share of opportunities ending in no decision at 53 percent (Challenger, 2024). Whichever number you trust, the headline is the same. The largest single thing standing between your team and quota is not the competition. It is a buyer who cannot get to yes, and a process that was never designed to notice.

So teams reach for the tools they have.

They run more demos. They add a discovery call. They hire another AE. They re-certify the team on the methodology. Each of those is a reasonable move inside the old frame, and not one of them touches the actual problem, because the problem is not that the rep failed to close. The problem is that the buyer was never equipped to decide, and no amount of pipeline volume fixes a readiness gap. The committee got larger, the buyer got more options, the rep got more pressure, and the deal got quieter.

The turn

So name it plainly. The reason the chart slid is not that your reps stopped closing.

It is that the field stopped defining selling as closing.

A deal with no readiness. A champion with no authority. A demo with no decision. A pipeline with no buyer who is ready to move. Your methodology can run all four of those situations flawlessly and still produce a no-decision, because the methodology measures whether the rep did the activity, not whether the buyer arrived ready to choose. The activity was never the constraint. The readiness was. And the readiness lives in the part of the process the playbook does not look at.

That is the rename. The work changed from getting the order to building the buyer's ability to decide. The researchers caught it. The certification decks did not.

What Holistic Selling gets right, and the gap it leaves open

Give the Kalwey paper its due, and give it its limits. It is theory-building work, drawn from qualitative interviews with executives and buyers and then validated, not a large-scale causal study. It tells you the shape of the new era. It does not yet prove, with experimental rigor, how much win rate the shift is worth. Anyone selling you a methodology should be this honest about the grade of their evidence, and most are not.

But the direction is solid, and it leaves one question wide open.

Holistic Selling says the seller's job is to make the buyer better at deciding. It does not tell you what is stopping this particular buyer from deciding. "Make the buyer better at deciding" is the right mandate and a useless instruction on a Tuesday with a deal stuck at week six. Better at what? Stuck on which part? The model names the new job. It does not hand you the instrument for the specific deal in front of you.

That is the seam. Holistic Selling and a buyer-readiness diagnostic are pointed at the same gap from opposite sides. One says the seller's job is to make the decision possible. The other tells you, on this deal, exactly where the decision is blocked.

What to actually work on

Decision avoidance is not one thing, which is why "the deal is just stalled" is a misread almost every time. Foundational work in Psychological Bulletin found that doing nothing breaks into four distinct behaviors, each with a different cause (Anderson, 2003). A buyer who defers because the cost of staying the same feels invisible is not the same as a buyer who freezes because they cannot tell the options apart. Treat them the same and you will apply the wrong fix to both.

So you measure. Buyer readiness resolves into four dimensions, and a deal moves at the speed of its weakest one.

1. Problem Conviction. Does the buyer believe the cost of doing nothing is real? A prospect who says the product is impressive but cannot tell you what staying the same is costing them is stalled here, not on price.

2. Evaluation Clarity. Does the buyer know how to choose? When they call the demo helpful but cannot name what they are comparing you against, the deal is blocked on clarity, and how a buyer evaluates decides what they end up valuing.

3. Outcome Confidence. Does the buyer believe it will work in their world? The prospect who spends every call on integrations and edge cases is telling you exactly which dimension is short.

4. Organizational Readiness. Can the buyer actually get this done internally? The champion who says "let me run it by the team" and disappears for two weeks ran into this wall, and a larger buying committee makes that wall taller.

Three of these can be maxed out and the fourth, left incomplete, still kills the deal. That is what it means to build the buyer's decision competence with precision instead of hope. You find the binding constraint and you work it, rather than running the whole playbook again and louder.

What to do with this on Monday

You do not need to rip out your methodology. You need to know what it is rooted in, and whether the root still holds.

Open your last ten lost deals. Filter for the ones that ended in no decision rather than a competitor win. Count them. If that number is more than a third of your losses, the issue is not execution of the play.

Name the foundation. Write down which methodology your process runs on and the decade it was authored in. Then ask whether it assumes a buyer who arrives uninformed and gets shaped by your rep, or a buyer who arrives 70 percent decided and wants help only at the moment of choice. If it assumes the first buyer, it is solving a problem your market no longer has.

Add the layer underneath. Keep the methodology for what it is good at, which is running the qualified conversation. Put a readiness diagnostic beneath it to answer the question the methodology cannot: not "is this deal qualified," but "where is this deal stuck."

Back to the room

Picture that QBR slide again. The logo. The chart drifting down and to the right. The plan to certify the reps who slipped.

The slide is not wrong. It is just answering a question from a model the field already replaced. The reps are running the play. The play is built for a buyer who stopped showing up around the time the research changed.

So put a different question on the screen. Not "are the reps running the methodology." The harder one. The one that decides whether next year's chart points the other way.

What is your methodology rooted in, and has its foundation moved without you?

The field already answered. The only question left is how long your pipeline pays for the gap before you do.

If you want to see where your deals actually stand, the four-minute buyer readiness assessment scores your pipeline against all four dimensions and names the one that is costing you the most.